老年人心脏自主神经活动时相的生物学特征

目的本研究旨在以心率变异性(HRV)为手段,探讨老年人心脏自主神经活动时相的生物学特征. 方法共入选2组健康受试者观察组33例,年龄65～82岁,平均(72±10)岁;对照组31例,26～35岁,平均(30±4)岁.对2组对象进行24h动态心电图监测,记录每小时HRV的频域指标(总功率TP,低频成分LF,高频成分HF,及LF/HF).采用余弦拟合法对所得数据进行处理. 结果 HRV的频域指标呈典型的昼夜节律分布;与年轻组相比,老年人TP,LF及HF的均值及振幅明显减低;LF/HF的振幅也减低,但其均值无显著变化.2组间各指标的相位无明显变化. 结论老年人HRV的24h均值及昼夜波动振幅渐低,而其相位不变.提示该人群中心脏自主神经兴奋水平及其对心血管功能的调节能力减低.     

Cytomegalovirus‐Responsive CD8+ T Cells Expand After Solid Organ Transplantation in the Absence of CMV Disease

Cytomegalovirus (CMV) is a major cause of morbidity and mortality in solid organ transplant recipients. Approximately 60% of adults are CMV seropositive, indicating previous exposure. Following resolution of the primary infection, CMV remains in a latent state. Reactivation is controlled by memory T cells in healthy individuals; transplant recipients have reduced memory T cell function due to chronic immunosuppressive therapies. In this study, CD8⁺ T cell responses to CMV polypeptides immediate‐early‐1 and pp65 were analyzed in 16 CMV‐seropositive kidney and heart transplant recipients longitudinally pretransplantation and posttransplantation. All patients received standard of care maintenance immunosuppression, antiviral prophylaxis, and CMV viral load monitoring, with approximately half receiving T cell–depleting induction therapy. The frequency of CMV‐responsive CD8⁺ T cells, defined by the production of effector molecules in response to CMV peptides, increased during the course of 1 year posttransplantation. The increase commenced after the completion of antiviral prophylaxis, and these T cells tended to be terminally differentiated effector cells. Based on this small cohort, these data suggest that even in the absence of disease, antigenic exposure may continually shape the CMV‐responsive T cell population posttransplantation.     

A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome

Background

The treatment of primary CNS lymphoma (PCNSL) comprises high dose methotrexate (HDMTX) based chemotherapy followed by whole brain radiotherapy (WBRT), the major drawback of which is long term neurotoxicity. We intended to assess the feasibility of response adapted WBRT in PCNSL in the Indian setting.

Methods

We screened 32 patients and enrolled 22 eligible patients with PCNSL from 2015 to 2017 in a prospective phase II trial. The patients underwent five 2-weekly cycles of induction chemotherapy with rituximab, methotrexate, vincristine, procarbazine. Patients with complete response(CR) to induction chemotherapy were given reduced dose WBRT 23.4 Gy/13 fractions/2.5 weeks while those with partial response (PR), stable or progressive disease (SD or PD) were given standard dose WBRT 45 Gy/25 fractions/5 weeks. Thereafter two cycles of consolidation chemotherapy with cytarabine were given. The primary endpoints of the study were assessment of response rate (RR) and progression free survival (PFS). The secondary endpoints of the study were assessment of overall survival (OS), toxicity profile of treatment and serial changes in quality of life and neuropsychological parameters.

Results

Out of 19 patients who completed HDMTX based chemotherapy, 10 (52.63%) patients achieved CR, 8 (42.11%) patients had PR and 1 patient had PD. After a median follow-up period of 11.25 months, the estimated median OS was 19 months. The actuarial rates of PFS and OS were respectively 94.1 and 68.2% at 1 year and 50.2 and 48.5% at 2 years. Three patients in reduced dose WBRT arm had recurrence and two of them died of progressive disease, whereas there was no recurrence or disease related death in standard dose WBRT arm. On univariate analysis of PFS, age?≤?50 years and use of standard dose WBRT (45 Gy) led to significantly improved outcome (p value 0.03 and 0.02 respectively).

Conclusion

In patients with PCNSL, reduced dose WBRT after CR to HDMTX based chemotherapy may lead to suboptimal clinical outcome due to higher risk of recurrence, progression and early death. Trial Registration No CTRI/2015/10/006268

     

Protective immunity in human filariasis: a role for parasite-specific IgA responses

BACKGROUND: Filaria-specific antibodies of immunoglobulin (Ig) G, IgE, and IgM isotypes have been correlated with acquired immunity in the literature, but the status of filaria-specific IgA and its role in human filariasis has not been addressed. The present study attempts to fill this lacuna. METHODS: Both total and filaria-specific IgA to different developmental stages of filarial parasites were quantified by solid-phase immunoassays in 412 clinically and parasitologically defined cases occurring in an area endemic for human bancroftian filariasis in Orissa, India. RESULTS: Compared with other clinical categories, microfilariae carriers were deficient in total as well as filaria-specific IgA. More crucially, significantly high levels were observed in putatively immune control subjects from areas of endemicity. These associations were also related to sex; female subjects in each category displayed higher levels of filaria-specific IgA than did male subjects. CONCLUSION: The study demonstrates, for the first time, a positive correlation between protective immunity and increased levels of filaria-specific IgA in human bancroftian filariasis. Furthermore, filaria-specific IgA appears to be an immunological window for the sex-related differences in susceptibility to infection observed in human filariasis.